Analysis of responses of pentoxifylline in the pulmonary vascular bed of the rat

American Journal of Therapeutics

Volumn 3, Issue 9, 1996, Pages 640-646

  Kaye, Alan D ^a,b   Feng, Chang J ^a   Smith, Donald E ^a   Kang, Bin ^a   Kadowitz, Philip J ^a   Nossaman, Bobby D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

hypoxia; N( ) L nitro L arginine benzyl ester; pentoxifylline; pulmonary hypertension; pulmonary vascular bed (rat); U 37833A; vasodilator responses

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ARACHIDONIC ACID; GLYCERYL TRINITRATE; ISOPRENALINE; LEMAKALIM; MECLOFENAMIC ACID; N (1 ADAMANTYL) N' CYCLOHEXYL 4 MORPHOLINECARBOXAMIDINE; N(G) LEVO NITRO LEVO ARGININE BENZYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY TONE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; HYPOXIA; INTRAARTERIAL DRUG ADMINISTRATION; ISOLATED LUNG; LUNG BLOOD VESSEL; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 0029958633     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199609000-00007     Document Type: Article

References (21)

1. Porter JM, Culter BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104: 66-72.
2. Ward A and Clissold SP: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987;34:50-97.
3. Masouye P, Gunning K, Pittet JF, Suter PM, Morel DR: The xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep. Circulatory Shock 1992;36:113-119.
4. Sigurdsson GH, Youssef H: Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock. Acta Anaesthesiol Scand 1993;37:396-403.
5. Rosenfeld BA, Toung TJ, Sendak MJ, Breslow MJ, Hutchins GM, Traystman RJ: Pentoxifylline attenuates edema formation in proteolytic enzyme-induced lung injury. Crit Care Med 1990;18(12):1394-1397.
6. Hakim TS, Petrella J: Attenuation of pulmonary and systemic vasoconstriction with pentoxifylline and aminophylline. Can J Physiol Pharmacol 1988;66:396-401.
7. Sturani C, Palareti G, Poggi M, Schiavine M, Torricelli P, Papiris S, Coccheri S, Gunella G: Pulmonary vascular reactivity and hemorheology in patients with chronic cor pulmonale: Response to pentoxifylline at rest and during exercise. Ric Clin Lab 1986;16:569-578.
8. Hakim TS: Reversal of pulmonary hypoxic vasoconstriction with pentoxifylline and aminophylline in isolated lungs. Can J Physiol Pharmacol 1988;66:146-151.
9. Crowell RE, Chick TW, Reed WP: Pentoxifylline relaxes isolated pulmonary arteries after preconstriction with norepinephrine. Respiration 1990;57:45-50.
10. Currie MS, Rao KMK, Padmanabhan J, Jones A, Crawford J, Cohen HJ: Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leuk Biol 1990;47:44-50.
11. Freedman SF, Hatchell DL: Enhanced superoxide radical production by stimulated polymorphonuclear leuko-cytes in a cat model of diabetes. Invest Ophthalmol Vis Chi 1991;32:1029.
12. 2) by pentoxifylline from human vascular tissues. Arzneimittelforshung 1982;32:1315-1318.
13. Sinzinger H: Pentoxifylline enhances formation of prosta-cyclin from rat vascular and renal tissue. Prostaglandins Leukot Med 1983;12:217-226.
14. Hoeffner U, Aarhus LL, Katusic ZS, Vanhoutte PM: Pharmacology of pentoxifylline in isolated canine arteries and veins. J Cardiovasc Pharmacol 1989;14:899-907.
15. Berkenboom G, Fang Z, Unger P, Goldman M, Fontaine J: Endothelium-dependent effects of pentoxifylline in rat aorta. Eur J Pharmacol 1991;193:81-86.
16. ω-L-nitro-L-arginine benzyl ester enhances pulmonary vasopressor responses to hypoxia and to angiotensin II. Am J Therap 1995;2:462-468.
17. Meskini N, Nemoz G, Okyayuz-Baklouti I: Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochemical Pharmacology 1994;47:781-788.
18. ω-L-nitro-L-arginine and pulmonary vascular pressure-flow relationship in conscious dogs. American Journal of Physiology 1992;62(31):H1331-1337.
19. Lippton H, Hao Q, Hyman A: L-NAME enhances pulmonary vasoconstriction without inhibiting EDRF-dependent vasodilation. Journal of Applied Physiology. 1992; 73(6):2432-2439.
20. ω-L-nitro-L-arginine methyl ester, LY 83583, glybenclamide and L 158809 on pulmonary circulation. European Journal of Pharmacology 1994;263:133-140.
21. Cheng D, DeWitt B, McMahon T, Kadowitz P: Comparitive effects of L-NNA and alkyl esters of L-NNA on pulmonary vasodilator responses to acetylcholine, bradykinin, and substance P. American Journal of Physiology 1994;266(35):H2416-H2422.